December

• "Compliments Muscle and Back Pain Relief Regular Strength": Labelling Error May Pose Serious Risks to Children [2011-12-29]
• North American Urgent Recall: Neonatal, Pediatric and Flextend Tracheostomy Tubes [2011-12-23]
• EpiPen and EpiPen Jr Auto-Injectors - Important Safety Information on Correct Usage - Pfizer Canada Inc.
  • For Health Professionals [2011-12-22]
  • For the Public [2011-12-22]
• Rasilez (aliskiren): Health Canada reviewing safety of blood-pressure drug [2011-12-22]
• Bisphosphonate osteoporosis drugs (Aclasta, Actonel, Didrocal, Fosamax, Fosavance): Small but increased risk of unusual thigh bone fractures [2011-12-19]
• Multaq (dronedarone) - Information on Important Revisions to Product Monograph - Sanofi-aventis Canada Inc.
  • For Health Professionals [2011-12-08]
  • For the Public [2011-12-08]
• AVASTIN (bevacizumab) - Reports of Cases of Severe Eye Inflammation Leading to Blindness Following Use in the Eye - Hoffmann-La Roche Ltd.
  • For Health Professionals [2011-12-07]
  • For the Public [2011-12-07]
• Ursodiol (ursodeoxycholic acid, UDCA) - Association of High-Dose with Serious Liver Side Effects - Aptalis Pharma Canada Inc., Dominion Pharmacal, Pharmascience Inc., Pharmel Inc., Teva Canada Ltd.
  • For Health Professionals [2011-12-05]
  • For the Public [2011-12-05]
• Sublinox (zolpidem tartrate) - Association with complex sleep behaviours - Meda Valeant Pharma Canada Inc.
  • For Health Professionals [2011-12-05]
  • For the Public [2011-12-05]

November

• "Stiff One Hard 169" Recalled From the Canadian Market: May Pose Serious Health Risks to Canadians [2011-11-30]
• Avastin (bevacizumab) - Health Canada has Suspended Approval for Use in Metastatic Breast Cancer - Hoffmann-La Roche Ltd.
  • For Health Professionals [2011-11-29]
• CooperVision Expands List of Contact Lenses [2011-11-16]
• Avastin (bevacizumab) - Higher Incidence of New Cases of Ovarian Failure Observed in Premenopausal Women - Hoffmann-La Roche Limited
  • For Health Professionals [2011-11-14]
  • For the Public [2011-11-14]
• Pradax (dabigatran etexilate) and Plavix (clopidogrel bisulfate) - Risk of Potential Patient Harm Associated with Brand Name Confusion - Boehringer Ingelheim (Canada) Ltd. and sanofi-aventis Canada Inc.
  • For Health Professionals [2011-11-08]
  • For the Public [2011-11-08]
• Fluoroquinolone antibiotics: patients with myasthenia gravis may risk increased muscle weakness [2011-11-07]

October

• Xigris (drotrecogin alfa [activated]) - Worldwide Withdrawal - Eli Lilly Canada Inc.
  • For Health Professionals [2011-10-28]
  • Notice to Hospitals [2011-10-28]
  • For the Public [2011-10-28]
• SynchroMed II Implantable Drug Infusion Pumps - Urgent Medical Device Correction Letter - Medtronic of Canada Ltd.
  • For Health Professionals [2011-10-26]
• Xigris (drotrecogin alfa) withdrawn worldwide [2011-10-25]
• STRATTERA (atomoxetine) - Association with Increased Blood Pressure and Increased Heart Rate - Eli Lilly Canada Inc.
  • For Health Professionals [2011-10-24]
  • For the Public [2011-10-24]
• Citalopram: Health Canada reviewing dose-related heart risk [2011-10-13]

September

• Plavix (blood thinner): New recommendations for use with PPIs (antacids) [2011-09-22]
• Trasylol (aprotinin) - Important New Safety Information - Bayer Inc.
  • Notice to Hospitals [2011-09-21]
  • For the Public [2011-09-21]
• Health Canada decision on Trasylol (aprotinin) [2011-09-21]
• GnRH Agonists: Heart-related Risk in Men Treated for Prostate Cancer [2011-09-08]
• Mesna (Uromitexan), Multi-Dose Vials - Association with Fatal Gasping Syndrome in Neonates and Infants - Baxter Corporation
  • For Health Professionals [2011-09-06]
  • For the Public [2011-09-06]

August

• Sprycel (dasatinib) - Safety Information Regarding Pulmonary Arterial Hypertension (PAH) - Bristol-Myers Squibb Canada
  • For Health Professionals [2011-08-30]
  • For the Public [2011-08-30]
• Central Vascular Access Devices - Complications of Catheter Pinch-off
  • Notice to Hospitals [2011-08-23]
• Certain Injectable and Inhalational Sterile Drugs Imported from Ben Venue Laboratories Inc. - Potential Supply Shortage
  • Notice to Hospitals [2011-08-18]
• Certain Sandoz Products for Injection - Possible Fading of the Expiry Date and Lot Number on Labels of Vials of 10 mL or Less - Sandoz Canada Inc.
  • For Health Professionals [2011-08-10]
• Multaq (dronedarone) - Information on Increase in Heart-Related Events in Patients with Permanent Atrial Fibrillation - Sanofi-aventis Canada Inc.
  • For Health Professionals [2011-08-04]
  • For the Public [2011-08-04]
• Finasteride (Propecia, Proscar): Potential rare risk of breast cancer in men [2011-08-04]

July

• Calcium Gluconate Injection 10% - Important Information Concerning the Presence of Aluminum
  • For Health Professionals [2011-07-28]
• Multaq: Health Canada reviewing heart-related risk [2011-07-21]
• Level 1 Normothermic I.V. Fluid Administration Sets equipped with F-50 Gas Vent Filter Assembly - Market Withdrawal - Smiths Medical Canada Ltd.
  • Notice to Hospitals [2011-07-21]
• Metoclopramide: Stronger warnings on risk of abnormal muscle movements [2011-07-20]

June

• Health Canada reviewing diabetes drug pioglitazone (Actos) and potential risk of bladder cancer [2011-06-17]
• Antipsychotic drugs: Labelling update regarding the risk of abnormal muscle movements and withdrawal symptoms in newborns exposed during pregnancy [2011-06-15]
• Health Canada reviewing safety of drospirenone-containing oral contraceptives (Yasmin and Yaz) and risk of venous thromboembolism [2011-06-07]
• RITUXAN (rituximab) - Fatal Infusion Related Reactions in Patients with Rheumatoid Arthritis - Hoffmann-La Roche Limited
  • For Health Professionals [2011-06-07]
  • For the Public [2011-06-07]

May

• Boston Scientific Urgent Device Notification - Non-Sterile Devices Stolen and Risk of Infection
  • Notice to Hospitals [2011-05-25]
• Cytarabine Injection - Crystallization in 2 g/20 mL (100 mg/mL) Vials - Hospira Healthcare Corporation
  • For Health Professionals [2011-05-11]

April

• ANZEMET (dolasetron mesylate) - Withdrawal of 20 mg/mL Intravenous Injection Due to Potential Risk of Arrhythmias - Sanofi-aventis Canada Inc.
  • For Health Professionals [2011-04-28]
  • For the Public [2011-04-28]
• Vivaglobin [Immune Globulin Subcutaneous (Human)] - Risk of Thrombotic Events (Blood Clots) - CSL Behring Canada, Inc.
  • For Health Professionals [2011-04-14]
  • For the Public [2011-04-14]
• RUSCH Irrigation Trays - Potential Contamination of Co-Packaged Alcohol Prep Pads - Teleflex Medical L. P.
  • Notice to Hospitals [2011-04-13]
• Bertec Model FLH668NDCM Medical Beds - Recall due to the Potential for the Head or Foot Section to Drop Unexpectedly - Stryker Canada
  • Notice to Hospitals [2011-04-06]

March

• Plum A+ Infusion Pumps - Recall Due to Audible Alarm Failure - Hospira Healthcare Corporation
  • Notice to Hospitals (Update) [2011-03-29]
  • Notice to Hospitals [2011-03-29]
• Immediate Recall by Mylan Pharmaceuticals: Potential Serious Risk due to Mislabelling of Products [2011-03-17]
• IXIARO Japanese Encephalitis Vaccine (inactivated, adsorbed) - Recall of Lot JEV09L37C - Novartis Pharmaceuticals Canada Inc.
  • For Health Professionals [2011-03-16]
  • For the Public [2011-03-16]
• Multaq (dronedarone) - Updated Safety Information in Regards to Hepatocellular Liver Injury - Sanofi-aventis Canada Inc.
  • For Health Professionals [2011-03-15]
  • For the Public [2011-03-15]

February

• Methylene blue injectable in combination with serotonin reuptake inhibitors - Association with serotonin toxicity
  • Notice to Hospitals [2011-02-17]
• PEGETRON REDIPEN (peginterferon alfa-2b) - Recall of Triad Group Alcohol Prep Pads, Alcohol Swabs, and Alcohol Swabsticks - Merck Canada Inc.
  • For Health Professionals [2011-02-04]
  • For the Public [2011-02-04]